Comments
Cadila Healthcare Ltd (Zydus Cadila), on Monday, said it has received final approval from the US Food and Drug Administration (USFDA) for Nateglinide tablets USP.
With this, the Ahmedabad-based company will be able to market Nateglinide tablets USP in strengths of 60 mg and 120 mg, according to a release here.
The drug is an oral anti-diabetic agent used in the management of Type 2 diabetes mellitus and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.